<DOC>
	<DOCNO>NCT02323178</DOCNO>
	<brief_summary>Treatment patient chronic myelomonocytic leukemia ( CMML ) thrombocytopenia .</brief_summary>
	<brief_title>A Study Eltrombopag Patients With CMML Thrombocytopenia</brief_title>
	<detailed_description>All eligible patient treat eltrombopag minimum twelve week maximum 24 month .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<criteria>Age 18 year old Chronic myelomonocytic leukemia ( CMML ) accord WHO criterion : Stable excess blood monocyte &gt; 1 G/L Lack bcrabl rearrangement ( Philadelphia chromosome ) Bone marrow blast cell &lt; 20 % Dysplasia least one lineage clonality marker blood monocytosis 3 month w/o explanation Platelet count &lt; 50 G/L two successive blood count 2 week precede inclusion Either D1 D2 criterion : Lack feature advanced disease If white blood cell count ( WBC ) &lt; 13 G/L : International Prognostic Scoring System ( IPSS ) low intermediate1 If WBC ≥ 13 G/L : one follow criterion : Clonal cytogenetic abnormality ( 5 ; 12 ) ( q33 ; p13 ) Absolute neutrophil count ( ANC ) &gt; 16 G/L Anemia ( Hb &lt; 100 g/L ) Extramedullary localization ( document cutaneous , pleural pericardial effusion , etc… ) OR D2 Features advance disease If WBC &lt; 13 G/L : IPSS intermediate2 high If WBC ≥ 13 G/L : two follow criterion : Clonal cytogenetic abnormality ( 5 ; 12 ) ( q33 ; p13 ) ANC &gt; 16 G/L Anemia ( Hb &lt; 100 g/L ) Extramedullary localization ( document cutaneous , pleural pericardial effusion , etc… ) And resist ( progression stable disease without hematological improvement accord International Working Group ( IWG ) 2006 criterion ) relapse treatment hypomethylating agent ( azacitidine decitabine minimum 6 cycle ) Blast cell ≤ 5 % bone marrow Performance status 02 Eastern Cooperative Oncology Group ( ECOG ) Scale Serum Creatinin &lt; 2 time upper limit normal ( ULN ) Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 3 ULN , total bilirubin &lt; 1.5 ULN ( except Gilbert Syndrome ) Adequate contraception relevant Signed informed consent CMML ( 5 ; 12 ) Plateletderived growth factor beta receptor ( PDGFbetaR ) rearrangement Acute blastic transformation CMML bone marrow blast cell &gt; 20 % Bone marrow blast cell &gt; 5 % Patients eligible allogeneic bone marrow transplantation identify donor Intensive chemotherapy give less 3 month inclusion Pregnant breastfeeding Hepatitis C infection Splenomegaly &gt; 16 cm ultrasound CT scan ( Not Applicable patient without palpable splenomegaly ) Significant ( grade IIIV ) myelofibrosis ( bone marrow trephine bone marrow aspirate poor cellularity , feature myelofibrosis peripheral blood smear ( teardrop erythrocyte ) Clinically relevant thromboembolic risk factor , investigator 's opinion , benefit/risk ratio become unfavourable platelet count increase Liver cirrhosis ( ChildPugh score ≥ 5 ) Prior Cancer ( except situ cervix carcinoma , limited basal cell carcinoma , tumor active last 3 year ) Serious concomitant systemic disorder , include active bacterial , fungal viral infection , opinion investigator , would compromise safety patient and/or his/her ability complete study . Hypersensitivity Eltrombopag</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic myelomonocytic leukemia</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>eltrombopag</keyword>
</DOC>